CONTENTS

Issue 94 | May 2020

In association with

Timeline

A brief history of mumps and mumps treatments in the UK

Pandemics

What happens to virus whistleblowers after they blow the whistle?

moving target

Peptomyc and the quest to develop a 'universal' cancer treatment

Eco-impact

Is pharma ready to tackle the health effects of continued climate change?

secret agents

Inactive pharmaceutical ingredients can make problems worse for patients 

Spin outs

After the year of the mega-merger, will 2020 be the year of the pharma spin out?

Q&A: Genocea

Improving cancer treatment with precise, personalised targets

development

An inside look at the Signals Analytics drug development playbook

IMDP

Turning attention towards patient benefits with IDMP data standards implementation

02/23/2024 23:48:02
  • Home | An (in)active pill problem
  • Editorial
  • SHL Group Company Insight
  • Scandinavian Health
  • Contents
  • NSF
  • News
  • Almac
  • Covid-19 executive briefing by GlobalData
  • Gerteis Company Insight
  • Gerteis
  • Digital biomarkers are emerging as important predictive tools to support the glo
  • Accurate Biometrics Company Insight
  • Accurate Biometrics
  • Almost 70 potential Covid-19 drug and experimental compound candidates identified
  • Datwyler Company Insight
  • Datwyler
  • Risk assessment of Covid-19 on patients suffering from IBD
  • Zenatek
  • The pharma industry briefing
  • Fargo
  • Another bump in the road for mumps treatment
  • Last Technology
  • From Covid-19 to SARS: what becomes of the whistleblowers?
  • Butterworth
  • Peptomyc: the quest for a ‘universal’ cancer treatment
  • Q&A: is pharma ready to address the health effects of climate change?
  • Modality Solutions
  • Not-so-inactive ingredients: a sore spot for patients?
  • Beyond M&As: will 2020 be the year of the spin-off?
  • VEGA Company Insight
  • VEGA Australia
  • Q&A with Genocea: improving cancer treatment with precise, personalised targets
  • Mimotopes
  • Pharma Playbook: an inside look at Signals Analytics vast therapeutic database
  • ILC Dover
  • Deals in brief powered by GlobalData
  • The key list powered by GlobalData
  • Global markets and indices powered by GlobalData
  • Macro-economic indicators (1 of 2) powered by GlobalData
  • Macro-economic indicators (2 of 2) powered by GlobalData
  • Events
  • Next issue
04/23/2020 00:00:00